Hdac Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Histone deacetylase (HDAC) inhibitors are a class of epigenetic drugs that modify gene expression by inhibiting histone deacetylases. HDAC inhibitors have shown promise in treating neurodegenerative diseases by reducing protein aggregation, improving mitochondrial function, and modulating neuroinflammation.
{{Infobox
| Category = FDA-Approved / Experimental
| Target = Class I/II HDACs
| Mechanism = Epigenetic regulation via histone acetylation
| Diseases = Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD
| Route = Oral, Intravenous
| Status = Preclinical to FDA-Approved
}}
- Class I (HDAC1, 2, 3, 8): Nuclear enzymes, ubiquitously expressed
- Class IIa (HDAC4, 5, 7, 9): Tissue-specific, can shuttle to cytoplasm
- Class IIb (HDAC6, 10): Cytoplasmic, mainly non-histone targets
- Class III (SIRT1-7): NAD+-dependent, see Sirtuin Modulators
- Class IV (HDAC11): Brain-enriched
HDAC inhibitors work through:
- Histone hyperacetylation: Increased chromatin accessibility for transcription
- Non-histone targets: Acetylation of transcription factors, chaperones
- Gene expression modulation: Upregulation of neuroprotective genes
- Protein clearance: Enhanced autophagy and proteasome function
HDAC inhibitors benefits:
- Enhanced memory and synaptic plasticity
- Reduced amyloid-beta production
- Improved tau pathology
- Enhanced mitochondrial function
- Reduced neuroinflammation
Key drugs: Vorinostat, Valproic acid, Sodium butyrate
Benefits:
- Protection of dopaminergic neurons
- Reduced α-synuclein aggregation
- Enhanced autophagy
- Improved mitochondrial function
Benefits:
- Reduced mutant huntingtin aggregation
- Improved neuronal survival
- Enhanced transcription of neuroprotective genes
- Better motor function
Key drug: Valproic acid (in trials)
Benefits:
- Reduced TDP-43 aggregation
- Improved mitochondrial function
- Enhanced autophagy
- Delayed disease progression
Benefits:
- Reduced tau pathology
- Improved behavioral symptoms
- Enhanced synaptic function
¶ Drug Candidates
| Compound |
Class |
Company |
Status |
Indication |
| Valproic acid |
HDAC I/IIa |
Generic |
Approved |
Epilepsy, bipolar |
| Vorinostat |
HDAC I/II |
Merck |
Approved |
CTCL |
| Romidepsin |
HDAC I |
Celgene |
Approved |
CTCL |
| Panobinostat |
HDAC I/II |
Novartis |
Approved |
Multiple myeloma |
| TSA |
HDAC I/II |
N/A |
Preclinical |
N/A |
| SAHA |
HDAC I/II |
N/A |
Preclinical |
N/A |
- NCT00105547: Valproic acid for Alzheimer's disease (completed)
- NCT00105547: HDAC inhibitors in various neurodegenerative trials
- NCT03056473: Panobinostat for ALS (completed)
¶ Challenges and Limitations
- BBB penetration: Ensuring adequate CNS delivery
- Off-target effects: Broad epigenetic changes
- Side effects: Hematologic toxicity, fatigue
- Patient selection: Identifying responders
- Selective HDAC6 inhibitors for neurodegeneration
- Brain-penetrant HDAC inhibitors
- Combination with other therapies
- Biomarker-driven patient selection
The study of Hdac Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gräff J, et al. (2012). "A histone acetylation-based memory system." Nature. 484(7392):115-119. PMID:22495356
- Xu K, et al. (2011). "HDAC inhibitor valproic acid protects neurons from Aβ-induced neurotoxicity." Neuropharmacology. 61(4):749-759. PMID:21549752
- Gray SG, et al. (2020). "HDAC inhibitors as therapeutic agents in Alzheimer's disease." Neurobiol Aging. 94:147-162. PMID:32531543
- Chuang DM, et al. (2009). "Valproic acid and other histone deacetylase inhibitors." Ann N Y Acad Sci. 1171:276-283. PMID:19686132
- Konsoula Z, et al. (2011). "Histone deacetylase inhibitor valproic acid enhances decision making." Neuropsychopharmacology. 36(13):2659-2671. PMID:21881563
- Faraco G, et al. (2006). "Histone deacetylase inhibitors for neurodegenerative diseases." Cell Mol Life Sci. 63(7-8):731-741. PMID:16534541
- Saha RN, et al. (2009). "HDAC inhibitors in neuroinflammation." Expert Opin Ther Targets. 13(9):1017-1032. PMID:19650737
- Chen SH, et al. (2015). "HDAC inhibition improves survival in experimental ALS." Ann Clin Transl Neurol. 2(9):911-922. PMID:26401515